PHARMACEUTICAL COMPOSITIONS WITH RESISTANCE TO SOLUBLE CEA
The present invention relates to pharmaceutical compositions for the treatment of an epithelial tumor in a human, said pharmaceutical composition comprising a bispecific single chain antibody which has a first binding domain specifically binding to human CD3, and a second binding domain specifically...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; por |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | EVELYNE SCHALLER PETER KUFER TOBIAS RAUM DORIS RAU PETRA MAYER ALEXANDER MURR SUSANNE MANGOLD RALF LUTTERBÜSE MONIKA WISSINGER |
| description | The present invention relates to pharmaceutical compositions for the treatment of an epithelial tumor in a human, said pharmaceutical composition comprising a bispecific single chain antibody which has a first binding domain specifically binding to human CD3, and a second binding domain specifically binding to human CEA, wherein said second binding domain comprises at least a part of the CDR-H3 or the complete CDR-H3 of murine monoclonal antibody A5B7. Furthermore, processes for the production of said pharmaceutical compositions as well as medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human CD3 antigen and the human CEA antigen are disclosed. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_PT1976880TT</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>PT1976880TT</sourcerecordid><originalsourceid>FETCH-epo_espacenet_PT1976880TT3</originalsourceid><addsrcrecordid>eNrjZLAK8HAM8nV0dg0N8XR29FFw9vcN8A_2DPH09wtWCPcM8VAIcg32DA5x9HN2VQjxVwj29wl18nFVcHZ15GFgTUvMKU7lhdLcDApuriHOHrqpBfnxqcUFicmpeakl8QEhhpbmZhYWBiEhxkQoAQCV6yl6</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>PHARMACEUTICAL COMPOSITIONS WITH RESISTANCE TO SOLUBLE CEA</title><source>esp@cenet</source><creator>EVELYNE SCHALLER ; PETER KUFER ; TOBIAS RAUM ; DORIS RAU ; PETRA MAYER ; ALEXANDER MURR ; SUSANNE MANGOLD ; RALF LUTTERBÜSE ; MONIKA WISSINGER</creator><creatorcontrib>EVELYNE SCHALLER ; PETER KUFER ; TOBIAS RAUM ; DORIS RAU ; PETRA MAYER ; ALEXANDER MURR ; SUSANNE MANGOLD ; RALF LUTTERBÜSE ; MONIKA WISSINGER</creatorcontrib><description>The present invention relates to pharmaceutical compositions for the treatment of an epithelial tumor in a human, said pharmaceutical composition comprising a bispecific single chain antibody which has a first binding domain specifically binding to human CD3, and a second binding domain specifically binding to human CEA, wherein said second binding domain comprises at least a part of the CDR-H3 or the complete CDR-H3 of murine monoclonal antibody A5B7. Furthermore, processes for the production of said pharmaceutical compositions as well as medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human CD3 antigen and the human CEA antigen are disclosed.</description><language>eng ; por</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2016</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20160928&DB=EPODOC&CC=PT&NR=1976880T$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25563,76318</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20160928&DB=EPODOC&CC=PT&NR=1976880T$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>EVELYNE SCHALLER</creatorcontrib><creatorcontrib>PETER KUFER</creatorcontrib><creatorcontrib>TOBIAS RAUM</creatorcontrib><creatorcontrib>DORIS RAU</creatorcontrib><creatorcontrib>PETRA MAYER</creatorcontrib><creatorcontrib>ALEXANDER MURR</creatorcontrib><creatorcontrib>SUSANNE MANGOLD</creatorcontrib><creatorcontrib>RALF LUTTERBÜSE</creatorcontrib><creatorcontrib>MONIKA WISSINGER</creatorcontrib><title>PHARMACEUTICAL COMPOSITIONS WITH RESISTANCE TO SOLUBLE CEA</title><description>The present invention relates to pharmaceutical compositions for the treatment of an epithelial tumor in a human, said pharmaceutical composition comprising a bispecific single chain antibody which has a first binding domain specifically binding to human CD3, and a second binding domain specifically binding to human CEA, wherein said second binding domain comprises at least a part of the CDR-H3 or the complete CDR-H3 of murine monoclonal antibody A5B7. Furthermore, processes for the production of said pharmaceutical compositions as well as medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human CD3 antigen and the human CEA antigen are disclosed.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2016</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZLAK8HAM8nV0dg0N8XR29FFw9vcN8A_2DPH09wtWCPcM8VAIcg32DA5x9HN2VQjxVwj29wl18nFVcHZ15GFgTUvMKU7lhdLcDApuriHOHrqpBfnxqcUFicmpeakl8QEhhpbmZhYWBiEhxkQoAQCV6yl6</recordid><startdate>20160928</startdate><enddate>20160928</enddate><creator>EVELYNE SCHALLER</creator><creator>PETER KUFER</creator><creator>TOBIAS RAUM</creator><creator>DORIS RAU</creator><creator>PETRA MAYER</creator><creator>ALEXANDER MURR</creator><creator>SUSANNE MANGOLD</creator><creator>RALF LUTTERBÜSE</creator><creator>MONIKA WISSINGER</creator><scope>EVB</scope></search><sort><creationdate>20160928</creationdate><title>PHARMACEUTICAL COMPOSITIONS WITH RESISTANCE TO SOLUBLE CEA</title><author>EVELYNE SCHALLER ; PETER KUFER ; TOBIAS RAUM ; DORIS RAU ; PETRA MAYER ; ALEXANDER MURR ; SUSANNE MANGOLD ; RALF LUTTERBÜSE ; MONIKA WISSINGER</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_PT1976880TT3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; por</language><creationdate>2016</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>EVELYNE SCHALLER</creatorcontrib><creatorcontrib>PETER KUFER</creatorcontrib><creatorcontrib>TOBIAS RAUM</creatorcontrib><creatorcontrib>DORIS RAU</creatorcontrib><creatorcontrib>PETRA MAYER</creatorcontrib><creatorcontrib>ALEXANDER MURR</creatorcontrib><creatorcontrib>SUSANNE MANGOLD</creatorcontrib><creatorcontrib>RALF LUTTERBÜSE</creatorcontrib><creatorcontrib>MONIKA WISSINGER</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>EVELYNE SCHALLER</au><au>PETER KUFER</au><au>TOBIAS RAUM</au><au>DORIS RAU</au><au>PETRA MAYER</au><au>ALEXANDER MURR</au><au>SUSANNE MANGOLD</au><au>RALF LUTTERBÜSE</au><au>MONIKA WISSINGER</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>PHARMACEUTICAL COMPOSITIONS WITH RESISTANCE TO SOLUBLE CEA</title><date>2016-09-28</date><risdate>2016</risdate><abstract>The present invention relates to pharmaceutical compositions for the treatment of an epithelial tumor in a human, said pharmaceutical composition comprising a bispecific single chain antibody which has a first binding domain specifically binding to human CD3, and a second binding domain specifically binding to human CEA, wherein said second binding domain comprises at least a part of the CDR-H3 or the complete CDR-H3 of murine monoclonal antibody A5B7. Furthermore, processes for the production of said pharmaceutical compositions as well as medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human CD3 antigen and the human CEA antigen are disclosed.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; por |
| recordid | cdi_epo_espacenet_PT1976880TT |
| source | esp@cenet |
| subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES |
| title | PHARMACEUTICAL COMPOSITIONS WITH RESISTANCE TO SOLUBLE CEA |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T14%3A05%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=EVELYNE%20SCHALLER&rft.date=2016-09-28&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EPT1976880TT%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |